Back to results
US 2008/0293757 A1Published application
Abca1 elevating compounds
OwnerMatthew Abelman, Robert Jiang +2inventors
InventorsMatthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
Claims35
A compound having the structure of Formula I:
- wherein:
- R1 and R2 are independently optionally substituted lower alkyl, optionally substituted aryl, optionally substituted alkenyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
- or
- R1 and R2 when taken together with the carbon atom to which they are attached represent a 5 or 6 membered carbocyclic or heterocyclic ring;
- R3, R4 and R5 are independently hydrogen, hydroxyl, optionally substituted lower alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, cyano, halo, —SO2—NR9R10, or —C(O)R11, in which R9 and R10 are independently hydrogen, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or may joint to form a 5 or 6 membered optionally substituted heterocyclic ring, and R11 is —OH or optionally substituted lower alkoxy;
- R6 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, —C(O)R12, or —S(O)2R13, in which R12 is optionally substituted lower alkyl, lower alkoxy or —NR14R15, in which R13, R14, and R15 are independently hydrogen, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, or R14 and R15 may join to form a 5 or 6 membered optionally substituted heterocyclic ring;
- R7 is hydrogen, hydroxyl, optionally substituted lower alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or —NR14R15;
- and
- R8 is hydrogen, cyano, optionally substituted lower alkyl, optionally substituted heterocyclyl, optionally substituted phenyl, —C(O)R11, —C(O)R14, —SR13, —OR13, —NR9S(S)2R10, —NR14C(O)NR14R15, —C(O)NR14R15, —CH2C(O)R11, —S(O)2R13, —B(OH)2, —C(CF3)2OH, —CH2P(O)(R11)2, halo, —NHC(O)R, —N[(CH2)2]2SO2, or —S(O)2NR9R10;
- or
- R7 and R8 may join together to form an optionally substituted 5 or 6 membered heterocyclic or heteroaryl ring;
- R20 is hydrogen, cyano, hydroxyl, halo, optionally substituted lower alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, —NR14R15, —C(O)R1, —C(O)R14, —SR14, —OR14, —C(S)R11, C(S)R14, —NR9S(O)2R10, —NR14C(O)NR14R14, —C(O)NR15R14, —C(S)NR15R14R15, —CH2C(O)R1, —S(O)2R13, B(OH)2, —C(CF3)2OH, —CH2P(O)(R11)2, —NHC(O)CH3, —N[(CH2)2]2SO2, or —S(O)2 NR9R10;
- A and D are independently 5 or 6 membered monocyclic heterocyclic, monocyclic heteroaryl, or monocyclic aryl rings;
- and
- X is oxygen, sulfur, —S(O)—, —S(O)2— or —NR16—, in which R16 is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, —C(O)R12, or —S(O)2R13.
12 more elements
The method of claim 35, wherein the disease state or condition is coronary artery disease or atherosclerosis.
Dependencies are inferred from the claim text.